NCT03608033: A reported trial by Omeros Corporation
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03608033 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 5, 2018 |
| Completion date | Jan. 12, 2024 |
| Required reporting date | Jan. 11, 2025, midnight |
| Actual reporting date | Jan. 10, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |